Organophosphate And Carbamate Poisoning - Pipeline Review, H1 2012
Global Markets Direct
January 23, 2012 28 Pages - SKU: GMD6776075
|
|
Organophosphate And Carbamate Poisoning - Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Organophosphate And Carbamate Poisoning - Pipeline Review, H1 2012', provides an overview of the Organophosphate And Carbamate Poisoning therapeutic pipeline. This report provides information on the therapeutic development for Organophosphate And Carbamate Poisoning, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Organophosphate And Carbamate Poisoning. 'Organophosphate And Carbamate Poisoning - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Organophosphate And Carbamate Poisoning.
- A review of the Organophosphate And Carbamate Poisoning products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Organophosphate And Carbamate Poisoning pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Organophosphate And Carbamate Poisoning.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Organophosphate And Carbamate Poisoning pipeline depth and focus of Organophosphate And Carbamate Poisoning therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
|
- Introduction
- Global Markets Direct Report Coverage
- Organophosphate And Carbamate Poisoning Overview
- Therapeutics Development
- An Overview of Pipeline Products for Organophosphate And Carbamate Poisoning
- Organophosphate And Carbamate Poisoning Therapeutics under Development by Companies
- Organophosphate And Carbamate Poisoning Therapeutics under Investigation by Universities/Institutes
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Organophosphate And Carbamate Poisoning Therapeutics - Products under Development by Companies
- Organophosphate And Carbamate Poisoning Therapeutics - Products under Investigation by Universities/Institutes
- Companies Involved in Organophosphate And Carbamate Poisoning Therapeutics Development
- MicroDose Therapeutx, Inc.
- Organophosphate And Carbamate Poisoning - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- Atropine Sulfate - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Clonidine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Organophosphate And Carbamate Poisoning Therapeutics - Drug Profile Updates
- Organophosphate And Carbamate Poisoning Therapeutics - Dormant Products
- Organophosphate And Carbamate Poisoning - Product Development Milestones
- Featured News & Press Releases
- Jun 07, 2011: MicroDose Therapeutx Announces Successful Completion Of Phase I Pilot Study Of Inhaled Atropine As Antidote To Combat Effects Of Nerve Agent Poisoning
- Jan 04, 2011: Protalix To Present PRX-105 Data At BARDA Industry Day
- Jun 08, 2010: Protalix Completes Phase I Clinical Trial For PRX-105
- Sep 23, 2009: MicroDose Therapeutx Announces Initiation Of Phase I Study With Inhaled Atropine As Antidote To Combat Effects Of Nerve Agent Poisoning
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Organophosphate And Carbamate Poisoning, H1 2012
- Products under Development for Organophosphate And Carbamate Poisoning - Comparative Analysis, H1 2012
- Number of Products under Development by Companies, H1 2012
- Number of Products under Investigation by Universities/Institutes, H1 2012
- Comparative Analysis by Mid Clinical Stage Development, H1 2012
- Comparative Analysis by Early Clinical Stage Development, H1 2012
- Products under Development by Companies, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- MicroDose Therapeutx, Inc., H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Organophosphate And Carbamate Poisoning Therapeutics - Drug Profile Updates
- Organophosphate And Carbamate Poisoning Therapeutics - Dormant Products
- List of Figures
- Number of Products under Development for Organophosphate And Carbamate Poisoning, H1 2012
- Products under Development for Organophosphate And Carbamate Poisoning - Comparative Analysis, H1 2012
- Products under Development by Companies, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Mid Clinical Stage Products, H1 2012
- Early Clinical Stage Products, H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Route of Administration, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Assessment by Stage and Molecule Type, H1 2012
Share this report
Other tasks Related Markets Drug Discovery Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|